RESPECT ESUS
This research is being done to compare the safety and efficacy of the drug dibigatran etexilate versus aspirin in patients with a condition called embolic stroke of undetermined source, a type of stroke when an artery supplying the blood to the brain becomes blocked and the origin of the blood clot is not identifiable. This study is open to patient’s ≥60 years old with an ischemic stroke of undetermined source up to 3 months or 6 in certain circumstances, prior to enrolling and who meet other medical criteria. Patients in the study will be followed for up to 3 years. This study is being sponsored by Boehringer Ingelheim. This trial is anticipated to begin enrollment in early 2015.
Back to Top